# Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

> **NCT02665702** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 76 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** NVB
- **DRUG:** DDP
- **DRUG:** Endostar

## Key facts

- **NCT ID:** NCT02665702
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01
- **Primary completion:** 2018-09
- **Final completion:** 2019-09
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2016-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02665702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02665702, "Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02665702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*